Press Releases

Date Title and Summary View
May 05, 2014
MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014
ROCKVILLE, Md. , May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation
Additional Formats
Apr 30, 2014
MacroGenics Appoints Atul Saran as Senior Vice President and General Counsel
ROCKVILLE, Md. , April 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has
Additional Formats
Apr 29, 2014
MacroGenics Announces Date of First Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md. , April 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014 , the Company will release its financial results for the quarter ended March 31, 2014 . The Company's management team will host a conference call discussing the Company's
Additional Formats
Apr 28, 2014
MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
ROCKVILLE, Md. , April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will
Additional Formats
Apr 06, 2014
MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
ROCKVILLE, Md. , April 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the
Additional Formats
Apr 01, 2014
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
ROCKVILLE, Md. , April 1, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim
Additional Formats
Mar 31, 2014
MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting

DART Product Candidate Is Being Developed for Treatment of Colorectal Cancer

Additional Formats
Mar 20, 2014
MacroGenics Provides Update on Corporate Progress and 2013 Financial Results
-- Six Immuno-Oncology Clinical Programs Projected by End of 2015 -- -- Cash Runway Extends Into 2017 -- ROCKVILLE, Md. , March 20, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal
Additional Formats
Mar 13, 2014
MacroGenics Announces Date of Year End 2013 Financial Results Conference Call
ROCKVILLE, Md. , March 13, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Thursday, March 20, 2014 , the Company will release its financial results for the year ended December 31, 2013 .  The Company's management team will host a conference call discussing the
Additional Formats
Mar 06, 2014
MacroGenics Appoints Matthew Fust to Its Board of Directors
ROCKVILLE, Md. , March 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit
Additional Formats
Mar 03, 2014
MacroGenics to Present at the 26th Annual ROTH Conference
ROCKVILLE, Md. , March 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jon
Additional Formats
Feb 12, 2014
MacroGenics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. , Feb. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the pricing of
Additional Formats
Feb 10, 2014
MacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , Feb. 10, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has
Additional Formats
Feb 05, 2014
MacroGenics Achieves Milestone as Servier Exercises Option to Develop and Commercialize DART-Based Candidate, MGD006
Successful Advancement of Lead DART Molecule and Option Exercise Triggers $20 Million in Payments MacroGenics Retains Full Rights to MGD006 in Multiple Major Markets ROCKVILLE, Md. and SURESNES, France , Feb. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Dec 11, 2013
MacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer

Data Featured in PLOS ONE Contribute to MacroGenics' Platform to Identify Monoclonal Antibodies that Target Cancer Stem Cells

Additional Formats
Dec 09, 2013
MacroGenics Announces Presentation of Pre-Clinical Data on DART(R) Molecule Targeting CD123-Positive Leukemic Stem Cells at 55th Annual Meeting of the American Society of Hematology

Results Support Clinical Development of MGD006 in Hematologic Malignancies

Additional Formats
Nov 12, 2013
MacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results
ROCKVILLE, Md. , Nov. 12, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate
Additional Formats
Nov 11, 2013
MacroGenics to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th ASH Annual Meeting
ROCKVILLE, Md. , Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that
Additional Formats
Nov 11, 2013
MacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate

Selection of a Pre-Clinical Development Candidate Triggers a $5 Million Milestone Payment

Additional Formats
Nov 05, 2013
MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call
ROCKVILLE, Md. , Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, November 12, 2013 , the Company will release its financial results for the third quarter ended September 30, 2013 . The Company's management team will host a conference call discussing
Additional Formats
Oct 16, 2013
MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option
ROCKVILLE, Md. , Oct. 16, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced the closing of its initial public offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to
Additional Formats
Oct 09, 2013
MacroGenics Announces Pricing of Initial Public Offering
MacroGenics Announces Pricing of Initial Public Offering ROCKVILLE, Md., October 9, 2013 - MacroGenics, Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $16.00 per share.
Additional Formats
Sep 19, 2013
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman

Dr. David C. Stump to join company’s Board of Directors

Additional Formats
Aug 20, 2013
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

Study to examine safety, pharmacokinetics and
anti-tumor effect of potential first-in-class B7-H3 targeted cancer immunotherapy

Additional Formats
Aug 12, 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development ROCKVILLE, Md., August 12, 2013 — MacroGenics, Inc. today announced that it has appointed Jon Wigginton, M.D., as Senior Vice President, Clinical Development. Dr.
Additional Formats